Foundry Partners LLC Sells 43,160 Shares of Avanos Medical, Inc. (NYSE:AVNS)

Foundry Partners LLC decreased its position in Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 26.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 119,870 shares of the company's stock after selling 43,160 shares during the period. Foundry Partners LLC owned approximately 0.26% of Avanos Medical worth $1,908,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in AVNS. Quarry LP acquired a new position in Avanos Medical in the third quarter valued at about $42,000. Quantbot Technologies LP acquired a new position in shares of Avanos Medical in the 4th quarter valued at approximately $64,000. KLP Kapitalforvaltning AS acquired a new position in shares of Avanos Medical in the 4th quarter valued at approximately $162,000. Intech Investment Management LLC bought a new stake in Avanos Medical during the 3rd quarter worth approximately $207,000. Finally, EP Wealth Advisors LLC acquired a new stake in Avanos Medical during the 3rd quarter worth approximately $212,000. Institutional investors own 95.17% of the company's stock.

Avanos Medical Stock Down 5.6 %

Shares of AVNS traded down $0.74 during midday trading on Thursday, hitting $12.44. The stock had a trading volume of 87,925 shares, compared to its average volume of 321,717. The company has a 50 day simple moving average of $15.04 and a two-hundred day simple moving average of $17.65. Avanos Medical, Inc. has a twelve month low of $12.09 and a twelve month high of $25.36. The firm has a market cap of $572.09 million, a price-to-earnings ratio of 36.66 and a beta of 1.15. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46.

Avanos Medical (NYSE:AVNS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.03. The company had revenue of $179.60 million for the quarter, compared to the consensus estimate of $177.23 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. On average, analysts anticipate that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th.

Insiders Place Their Bets

In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the transaction, the senior vice president now owns 82,047 shares of the company's stock, valued at $1,251,216.75. The trade was a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.64% of the company's stock.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.